<DOC>
	<DOCNO>NCT01437787</DOCNO>
	<brief_summary>Primary Objective : - To evaluate efficacy daily oral dos 400 mg 500 mg SAR302503 ( Investigational Medicinal Product , IMP ) compare placebo reduction spleen volume determine magnetic resonance imaging ( MRI ) ( compute tomography scan patient contraindication MRI ) . Secondary Objectives : - To evaluate effect Myelofibrosis ( MF ) -associated symptom ( key MF symptom ) measure modified Myelofibrosis Symptom Assessment Form ( MFSAF ) diary . - To evaluate Overall Survival patient treat either 400 mg/day 500 mg/day IMP compare placebo . - To evaluate Progression Free Survival patient treat either 400 mg/day 500 mg/day IMP compare placebo . - To evaluate durability splenic response . - To evaluate safety IMP .</brief_summary>
	<brief_title>Phase III Study SAR302503 Intermediate-2 High Risk Patients With Myelofibrosis</brief_title>
	<detailed_description>The expected duration patient 's treatment study approximately 8 month , base maximum 28-day screening period , follow ≥6-month ( 6-cycle ) treatment period , End Of Treatment ( EOT ) visit , perform least 30 day follow last administration IMP placebo . Patients continue benefit clinically allow remain IMP placebo beyond 6-month treatment period occurrence disease progression unacceptable toxicity .</detailed_description>
	<mesh_term>Primary Myelofibrosis</mesh_term>
	<mesh_term>Hematologic Neoplasms</mesh_term>
	<criteria>Inclusion criterion : Diagnosis Primary Myelofibrosis ( MF ) PostPolycythemia Vera MF PostEssential Thrombocythemia MF , accord 2008 World Health Organization International Working Group Myelofibrosis Research Treatment ( IWGMRT ) criterion . MF classify highrisk intermediaterisk level 2 , define modify IWGMRT criterion ( IPSS ) ( accord Cervantes F. et . al . ; screen ) . Enlarged spleen , palpable least 5 cm costal margin . At least 18 year age . Eastern Cooperative Oncology Group performance status 0 , 1 , 2 study entry . The following laboratory value within 14 day prior initiation IMP placebo : Absolute Neutrophil Count ( ANC ) ≥1.0 x 10exp9/L Platelet count ≥50 x 10exp9/L Serum creatinine ≤1.5 x Upper Limit Normal ( ULN ) Serum amylase lipase ≤1.5 x ULN Exclusion criterion : Splenectomy . Any chemotherapy ( eg , hydroxyurea ) , immunomodulatory drug therapy ( eg , thalidomide , interferonalpha ) , Anagrelide , immunosuppressive therapy , corticosteroid &gt; 10 mg/day prednisone equivalent , growth factor treatment ( eg , erythropoietin ) , hormone ( eg , androgen , danazol ) within 14 day prior initiation IMP placebo ; darbepoetin use within 28 day prior initiation IMP placebo . Patients exposure hydroxyurea ( eg , hydrea ) past may enrol study long administer within 14 day prior initiation IMP placebo . Major surgery within 28 day radiation within 6 month prior initiation IMP placebo . Prior treatment Janus Kinase 2 ( JAK2 ) inhibitor . Known active ( acute chronic ) Hepatitis A , B , C ; hepatitis B C carrier AST ALT ≥2.5 x ULN Total Bilirubin : Exclude ≥3.0 x ULN Patients total bilirubin 1.53.0 x ULN must exclude direct bilirubin fraction ≥25 % total Prior history chronic liver disease ( eg , chronic alcoholic liver disease , autoimmune hepatitis , sclerosing cholangitis , primary biliary cirrhosis , hemachromatosis , nonalcoholic steatohepatitis [ NASH ] ) The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>